METHYCLOTHIAZIDE AND DESERPIDINE Drug Patent Profile

When do Methyclothiazide And Deserpidine patents expire, and when can generic versions of Methyclothiazide And Deserpidine launch?

Methyclothiazide And Deserpidine is a drug marketed by Watson Labs and is included in two NDAs.

The generic ingredient in METHYCLOTHIAZIDE AND DESERPIDINE is deserpidine; methyclothiazide. There is one drug master file entry for this compound. Additional details are available on the deserpidine; methyclothiazide profile page.

Summary for METHYCLOTHIAZIDE AND DESERPIDINE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	6
DailyMed Link:	METHYCLOTHIAZIDE AND DESERPIDINE at DailyMed

US Patents and Regulatory Information for METHYCLOTHIAZIDE AND DESERPIDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	METHYCLOTHIAZIDE AND DESERPIDINE	deserpidine; methyclothiazide	TABLET;ORAL	088486-001	Aug 10, 1984		DISCN	No	No
Watson Labs	METHYCLOTHIAZIDE AND DESERPIDINE	deserpidine; methyclothiazide	TABLET;ORAL	088452-001	Aug 10, 1984		DISCN	No	No

Methyclothiazide and Deserpidine Market Dynamics, Patent Status, and Financial Trajectory

Last updated: August 26, 2026

Methyclothiazide and deserpidine is a legacy antihypertensive combination with no meaningful current commercial market in the United States. Its historical value came from combining a thiazide diuretic, methyclothiazide, with a rauwolfia-derived sympatholytic, deserpidine. The product class lost share as physicians adopted beta blockers, ACE inhibitors, calcium-channel blockers, angiotensin-receptor blockers, and newer thiazide-like diuretics.

No current revenue, active exclusivity, or material generic-launch opportunity is publicly associated with the fixed-dose combination. The principal commercial conclusion is that methyclothiazide-deserpidine is an obsolete product rather than an investable pharmaceutical asset.

What is methyclothiazide and deserpidine?

Methyclothiazide and deserpidine is an oral fixed-dose antihypertensive combination historically marketed under the brand name Diupres. Methyclothiazide is a thiazide diuretic that lowers blood pressure by increasing urinary sodium and water excretion. Deserpidine is a rauwolfia alkaloid that reduces sympathetic nervous-system activity.

Attribute	Methyclothiazide and deserpidine
Therapeutic area	Hypertension
Drug type	Fixed-dose combination
Key ingredients	Methyclothiazide and deserpidine
Historical brand	Diupres
Dosage form	Oral tablets
Regulatory era	Mid-20th-century antihypertensive market
Current U.S. commercial status	No material active market identified
Patent-based exclusivity	Expired or commercially irrelevant
Biosimilar exposure	None
Principal substitutes	Hydrochlorothiazide, chlorthalidone, indapamide, ACE inhibitors, ARBs, calcium-channel blockers

The product belongs to an earlier generation of combination antihypertensives. Its clinical profile is less competitive than current therapies because deserpidine can produce central nervous-system and autonomic adverse effects associated with rauwolfia compounds.

When did methyclothiazide and deserpidine lose exclusivity?

The combination’s patent and regulatory exclusivity would have expired many decades ago. It was commercialized during the period when antihypertensive products were protected primarily by older composition, formulation, and manufacturing patents. Those rights are no longer relevant to market entry.

The product has no meaningful modern exclusivity comparable with a new chemical entity, pediatric exclusivity period, orphan-drug period, or biologic reference-product period. Any current manufacturer would face a mature generic environment with limited pricing power.

Historical exclusivity timeline

Period	Market event
1950s-1960s	Thiazide diuretics and rauwolfia-derived antihypertensives enter routine clinical use
1960s-1970s	Fixed-dose products such as Diupres compete in a growing hypertension market
1970s-1980s	Beta blockers and other cardiovascular therapies reduce reliance on rauwolfia combinations
1980s-1990s	ACE inhibitors and calcium-channel blockers gain market share
1990s-2000s	ARBs and modern fixed-dose combinations expand treatment options
Current period	Methyclothiazide-deserpidine has no material branded market position

No credible commercial case exists for patent-term extension, regulatory exclusivity, or a new product cycle based on the legacy combination.

What is the FDA regulatory status of methyclothiazide and deserpidine?

The combination is not a meaningful current U.S. marketed product. Historical labeling and pharmaceutical references identify Diupres as a methyclothiazide-deserpidine tablet, but the product does not have the commercial visibility of an actively marketed FDA-approved antihypertensive.

The FDA’s discontinued-drug and product databases are important for distinguishing historical approval from current commercial availability. A product can remain present in historical FDA records while having no active manufacturer, no current sales, and no practical prescription volume.[1]

The regulatory profile has four implications:

1. Historical approval does not establish current commercial availability.
2. A discontinued combination does not automatically create a modern generic opportunity.
3. Reintroduction could require regulatory, manufacturing, stability, labeling, and pharmacovigilance work.
4. A sponsor would need to demonstrate a commercially credible clinical rationale against established antihypertensive alternatives.

What patents protect methyclothiazide and deserpidine?

No active patent estate is commercially relevant to the legacy combination. Any original patents covering methyclothiazide, deserpidine, their use in hypertension, or their tablet formulation would have expired long ago.

Composition patents

Methyclothiazide and deserpidine are old small molecules. Their composition-of-matter protection is historical and cannot support current exclusivity.

Formulation patents

The tablet combination may have been covered historically by formulation or dosage patents. Those rights would also be expired. There is no evident modern extended-release, transdermal, implantable, or controlled-delivery platform attached to the product.

Method-of-use patents

Historical use in hypertension does not create present-day market protection. A new method-of-use patent would require a new, non-obvious therapeutic indication or dosing strategy. No commercially established modern indication is associated with the combination.

Orange Book status

The Orange Book is the principal U.S. reference for approved drug products and listed patents relevant to abbreviated new drug applications. Methyclothiazide-deserpidine does not have a current Orange Book profile comparable with actively marketed branded drugs that list unexpired patents or regulatory exclusivity.[2]

The absence of a meaningful Orange Book patent position eliminates the main mechanism through which an innovator could delay an ANDA-based generic launch.

Are there Paragraph IV challenges or generic litigation?

No material modern Paragraph IV litigation is associated with methyclothiazide and deserpidine. Paragraph IV litigation generally arises when an ANDA applicant challenges an unexpired Orange Book patent. The legacy combination lacks the commercial conditions that normally generate such disputes.

Litigation issue	Assessment
Active branded product	No material current product identified
Unexpired listed patents	No commercially relevant rights identified
Paragraph IV activity	No material current activity identified
Patent settlement agreements	No material modern settlements identified
Hatch-Waxman litigation	No meaningful current dispute identified
Launch blocking risk	Low from patent rights; high from commercial unattractiveness

Any potential reentrant would face ordinary regulatory and market-access barriers rather than patent litigation. A manufacturer could still encounter manufacturing, sourcing, quality, labeling, and pharmacovigilance requirements.

How strong is the patent estate for methyclothiazide and deserpidine?

The patent estate is effectively weak for present-day commercial purposes. Its weakness is structural rather than litigation-specific.

Patent-strength factor	Current assessment
New chemical entity protection	Expired
Composition-of-matter claims	Expired
Fixed-dose combination claims	Expired or commercially irrelevant
Formulation claims	No material active estate identified
Method-of-use claims	No material active estate identified
Patent-term adjustment or extension	Not commercially relevant
Freedom to launch a generic	Generally favorable from an expiry perspective
Ability to defend premium pricing	Very limited

Patent freedom does not equal commercial attractiveness. The absence of patent barriers may permit entry, but the product’s weak clinical differentiation and low expected demand reduce the value of that freedom.

What caused the commercial decline of the combination?

The product lost relevance through therapeutic substitution, safety concerns, and generic price erosion.

Therapeutic substitution

Hypertension treatment moved toward drugs with better tolerated and more predictable profiles. Current guideline-based treatment commonly uses thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers. Chlorthalidone and indapamide are often considered more durable diuretic options than older thiazides, while ACE inhibitors and ARBs provide broader use across cardiovascular and renal-risk populations.[3,4]

Deserpidine did not retain a preferred role because rauwolfia alkaloids can cause depression, sedation, nasal congestion, gastrointestinal effects, and other autonomic or central adverse events. These liabilities reduced physician demand as alternatives expanded.

Generic price erosion

Methyclothiazide and deserpidine are not protected by current exclusivity. Even if a manufacturer maintained a listed product, expected pricing would be constrained by:

• Low clinical differentiation
• Low prescribing frequency
• Small pharmacy inventory demand
• Limited payer incentive
• Established substitutes
• Potential raw-material and quality-control costs
• Small market size relative to regulatory overhead

Prescriber behavior

Modern hypertension management emphasizes cardiovascular risk reduction, comorbidity management, adherence, and fixed-dose combinations with widely used agents. A methyclothiazide-deserpidine product does not align well with current prescribing patterns.

What is the financial trajectory of methyclothiazide and deserpidine?

The financial trajectory is best characterized as historical decline followed by commercial disappearance.

Financial phase	Commercial condition
Initial launch	Revenue supported by a growing hypertension diagnosis base and limited therapeutic competition
Expansion phase	Fixed-dose convenience supported prescribing
Competitive decline	Beta blockers, ACE inhibitors, calcium-channel blockers, and ARBs captured demand
Mature generic phase	Price compression and reduced differentiation
Current period	No material branded revenue stream identified

No reliable public revenue series is associated with the combination. Historical sales may have been reported within broader cardiovascular portfolios rather than as a separately disclosed product. This prevents a precise peak-sales estimate or compound annual decline calculation.

The product also lacks the characteristics that create meaningful licensing value:

• No active patent moat
• No differentiated delivery technology
• No growing indication
• No orphan population
• No biologic or biosimilar platform
• No strategic manufacturing advantage
• No apparent clinical-development program

A transaction involving the product would likely be an asset-transfer or legacy-product transaction rather than a growth-oriented licensing deal. The value would depend on residual geographic registrations, manufacturing know-how, supply arrangements, and access to niche markets.

Which companies compete with methyclothiazide and deserpidine?

The relevant competitive landscape is therapeutic rather than brand-specific. The main substitutes are:

Drug class	Examples	Competitive advantage
Thiazide diuretics	Hydrochlorothiazide, methyclothiazide	Familiarity, low cost
Thiazide-like diuretics	Chlorthalidone, indapamide	Longer duration or stronger guideline positioning
ACE inhibitors	Lisinopril, enalapril	Broad cardiovascular and renal use
ARBs	Losartan, valsartan, irbesartan	Tolerability and combination flexibility
Calcium-channel blockers	Amlodipine, felodipine	Strong blood-pressure efficacy
Beta blockers	Metoprolol, atenolol	Selected cardiovascular indications

Current market share is concentrated in generic products with broad physician familiarity and extensive payer coverage. Methyclothiazide-deserpidine competes poorly against these products on efficacy perception, tolerability, treatment flexibility, and commercial scale.

What generic entry risks exist?

Patent-based launch risk is low because the legacy rights are expired. Commercial reentry risk is higher.

A generic manufacturer would need to address:

• Drug-substance sourcing for both active ingredients
• Consistent combination-tablet content uniformity
• Stability and impurity control
• Historical labeling reconstruction
• FDA application requirements
• Limited demand forecasting
• Pharmacy-channel distribution
• Pharmacovigilance for older adverse-effect concerns
• Potential difficulty securing economically viable manufacturing volume

The most likely launch scenario would be a niche, low-volume product supplied by a specialty or legacy-generic manufacturer. A broad commercial launch is unlikely without a defined institutional, geographic, or supply-contract customer base.

Does the product have biosimilar risk?

No. Methyclothiazide and deserpidine are chemically synthesized small molecules, not biologics. The relevant regulatory pathway is an abbreviated or full small-molecule drug application, not a biosimilar application under the Public Health Service Act.

The product has generic risk, not biosimilar risk. That distinction matters because there is no reference-biologic interchangeability framework, biologic exclusivity period, or biosimilar substitution issue associated with this combination.

What geographic markets could support the product?

The United States appears commercially unattractive. Potential residual demand, if any, would be more likely in jurisdictions where older antihypertensive products remain listed, supplied, or used in lower-cost treatment settings.

Geographic opportunity would depend on:

• Local registration status
• National essential-medicines policy
• Availability of approved active ingredients
• Local manufacturing capacity
• Procurement contracts
• Physician familiarity with deserpidine
• Adverse-event and labeling requirements
• Competition from inexpensive single-agent therapies

No broad international growth thesis is evident. A country-specific opportunity would require an existing registration or contracted demand base rather than general market expansion.

Key Takeaways

• Methyclothiazide and deserpidine is a legacy fixed-dose antihypertensive combination historically associated with Diupres.
• The combination has no meaningful current U.S. branded market position.
• Original composition, formulation, and use patents are expired or commercially irrelevant.
• No material current Paragraph IV litigation or patent-settlement activity is associated with the product.
• The main commercial threats are therapeutic substitution and low demand, not patent infringement.
• Deserpidine’s tolerability profile and obsolete clinical positioning weakened the product against modern antihypertensive therapies.
• No reliable standalone public revenue series supports a precise financial forecast.
• Generic reentry is technically possible but commercially unattractive without niche demand, a supply contract, or an established geographic registration.
• The product has no biosimilar exposure because both ingredients are small-molecule drugs.
• The financial trajectory is historical decline followed by practical commercial discontinuation.

FAQs

Is methyclothiazide and deserpidine still prescribed?

It is not a mainstream current antihypertensive therapy. Modern treatment has shifted toward thiazide-like diuretics, ACE inhibitors, ARBs, calcium-channel blockers, and selected beta blockers.

What was the brand name for methyclothiazide and deserpidine?

The combination was historically marketed as Diupres.

Can a generic company launch methyclothiazide and deserpidine?

A launch may be possible from a patent-expiry perspective, but the product would still require regulatory approval, compliant manufacturing, validated supply, and sufficient demand. Its commercial prospects are limited.

Is deserpidine the same as reserpine?

No. Deserpidine and reserpine are related rauwolfia alkaloids, but they are different active substances with different chemical identities and product histories.

Is methyclothiazide and deserpidine listed in the FDA Orange Book?

It does not have a current Orange Book profile comparable with actively marketed branded products protected by unexpired listed patents or regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2024). FDA discontinued drug product list.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
4. World Health Organization. (2021). Guideline for the pharmacological treatment of hypertension in adults. WHO.